← All earnings call summaries
Solara Active Pharma Sciences Limited — Q1FY27 Earnings Call Summary
Key Takeaways
- Capex INR55-60 Cr in FY27; focus on debottlenecking capacity with 20-30% volume increase
- Q1 FY27 revenue INR384 Cr +20% y-y; EBITDA INR63.5 Cr +10% y-y; PAT INR16.3 Cr +55% y-y
- Ibuprofen business EBITDA margin negative 12%, expected loss INR10-15 Cr per quarter
- Net debt reduced by INR135 Cr (22%) to INR479 Cr; target sub INR450 Cr by Mar-27
- Strategic review of ibuprofen business expected by H1 FY27; options being evaluated
- Base business capacity utilization ~70%; Vizag facility mothballed pending strategic decisions
- Management cautious on West Asia crisis impact; transparent pricing pass-through ongoing
- Base business revenue INR307 Cr +24% y-y; EBITDA INR72 Cr +8% y-y; gross margin ~52-55%
📄 Source: View original transcript (PDF)
Get Solara Active Pharma Sciences Limited earnings summaries on Telegram
Add Solara Active Pharma Sciences Limited to your watchlist. Receive AI-generated summaries within hours of every earnings call.
Start free →
Summary generated by AI from the official transcript filed on BSE/NSE. Not investment advice.